Uso de etanercept en amiloidosis secundarias a artritis reumatoide: a propósito de dos casos

Fernández, Inmaculada Macías; Rodríguez, Antonia María Fernández; Pérez, Sergio García

doi:10.1016/j.reuma.2010.12.005

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the available treatments are corticosteroids, cytostatic drugs, and monoclonal antibody cytokines (TNF and IL-6). 3 , 6 , 7 , 8 , 9 , 10 Our patient developed secondary systemic amyloidosis during treatment of the underlying disease with etanercept, which shows that the disease was extremely aggressive in this case. Therefore, the early diagnosis was essential to prevent damage to other organs.…”

Section: Discussionmentioning

confidence: 68%

Systemic amyloidosis manifestation in a patient with psoriatic arthritis

Souza

Gavioli

Oliveira

et al. 2021

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

Systemic amyloidosis secondary to psoriatic arthritis is rare, and published data are based mainly on case reports and are associated with increased mortality. This is the report of a patient with long-term psoriatic arthritis and chronic sialadenitis, who showed an inadequate response to therapy. The diagnosis of secondary amyloidosis was attained through biopsies of genital skin lesions. Although very rare, it is important that dermatologists and general practitioners consider the possibility of amyloidosis in patients with chronic inflammatory diseases, since an early intervention can be implemented, and thus, the prognosis of this condition can be improved.

show abstract

Section: Discussionmentioning

confidence: 68%

Systemic amyloidosis manifestation in a patient with psoriatic arthritis

Souza

Gavioli

Oliveira

et al. 2021

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

show abstract

“…Our patient had a short duration and nonerosive arthritis at amyloidosis diagnosis, which however could have been a subclinical disease. Rheumatoid arthritis therapeutics aims to achieve disease remission by suppressing inflammation and immunological dysregulation [ 10 ]. Sulphasalazine was initially chosen instead of methotrexate, either due to the patient's refusal of that drug or due to the potentially limiting pulmonary drug toxicity.…”

Section: Discussionmentioning

confidence: 99%

Intestinal Amyloidosis in Common Variable Immunodeficiency and Rheumatoid Arthritis

Meira

Sousa

Cordeiro

et al. 2015

Case Reports in Gastrointestinal Medicine

View full text Add to dashboard Cite

We present a case of reactive amyloidosis that developed secondary to common variable immunodeficiency and rheumatoid arthritis. A 66-year-old woman, with prior history of common variable immunodeficiency and rheumatoid arthritis, was referred to our clinic for chronic diarrhea investigation. The patient was submitted to colonoscopy with ileoscopy, which did not show relevant endoscopic alterations. However, undertaken biopsies revealed amyloid deposition. Since amyloidosis with GI involvement is a rare cause of chronic diarrhea, this pathology should be considered in etiologic investigation, especially when associated with chronic inflammatory diseases.

show abstract